Cargando…

C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma

BACKGROUND: The C‐reactive protein : albumin ratio (CAR) has been reported as a novel prognostic marker in several cancers. The aim of this study was to investigate the prognostic value of CAR in patients with intrahepatic cholangiocarcinoma (ICC). METHODS: This was a single‐centre retrospective stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, T., Itoh, S., Yoshizumi, T., Kurihara, T., Yoshiya, S., Mano, Y., Takeishi, K., Harada, N., Ikegami, T., Soejima, Y., Baba, H., Mori, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709369/
https://www.ncbi.nlm.nih.gov/pubmed/32959537
http://dx.doi.org/10.1002/bjs5.50348
_version_ 1783617734479708160
author Matsumoto, T.
Itoh, S.
Yoshizumi, T.
Kurihara, T.
Yoshiya, S.
Mano, Y.
Takeishi, K.
Harada, N.
Ikegami, T.
Soejima, Y.
Baba, H.
Mori, M.
author_facet Matsumoto, T.
Itoh, S.
Yoshizumi, T.
Kurihara, T.
Yoshiya, S.
Mano, Y.
Takeishi, K.
Harada, N.
Ikegami, T.
Soejima, Y.
Baba, H.
Mori, M.
author_sort Matsumoto, T.
collection PubMed
description BACKGROUND: The C‐reactive protein : albumin ratio (CAR) has been reported as a novel prognostic marker in several cancers. The aim of this study was to investigate the prognostic value of CAR in patients with intrahepatic cholangiocarcinoma (ICC). METHODS: This was a single‐centre retrospective study of patients who underwent surgery for ICC in a university hospital in Japan between 1998 and 2018. CAR, Glasgow Prognostic Score (GPS) and modified GPS (mGPS) were calculated. Their correlation with recurrence‐free survival (RFS) and overall survival (OS) was analysed with Cox proportional hazards models. RESULTS: Seventy‐two patients were included in the study. Patients were divided into two groups according to the optimal CAR cut‐off value of 0·02. CAR above 0·02 was associated with higher carbohydrate antigen 19‐9 levels (20·5 versus 66·1 units/ml for CAR of 0·02 or less; P = 0·002), larger tumour size (3·2 versus 4·4 cm respectively; P = 0·031) and a higher rate of microvascular invasion (9 of 28 versus 25 of 44; P = 0·041). RFS and OS were shorter in patients with CAR above 0·02: hazard ratio (HR) 4·31 (95 per cent c.i. 2·02 to 10·63) and HR 4·80 (1·85 to 16·40) respectively. In multivariable analysis CAR above 0·02 was an independent prognostic factor of RFS (HR 3·29 (1·33 to 8·12); P < 0·001), but not OS. CONCLUSIONS: CAR was associated with prognosis in patients who had hepatic resection for ICC.
format Online
Article
Text
id pubmed-7709369
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-77093692020-12-09 C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma Matsumoto, T. Itoh, S. Yoshizumi, T. Kurihara, T. Yoshiya, S. Mano, Y. Takeishi, K. Harada, N. Ikegami, T. Soejima, Y. Baba, H. Mori, M. BJS Open Original Articles BACKGROUND: The C‐reactive protein : albumin ratio (CAR) has been reported as a novel prognostic marker in several cancers. The aim of this study was to investigate the prognostic value of CAR in patients with intrahepatic cholangiocarcinoma (ICC). METHODS: This was a single‐centre retrospective study of patients who underwent surgery for ICC in a university hospital in Japan between 1998 and 2018. CAR, Glasgow Prognostic Score (GPS) and modified GPS (mGPS) were calculated. Their correlation with recurrence‐free survival (RFS) and overall survival (OS) was analysed with Cox proportional hazards models. RESULTS: Seventy‐two patients were included in the study. Patients were divided into two groups according to the optimal CAR cut‐off value of 0·02. CAR above 0·02 was associated with higher carbohydrate antigen 19‐9 levels (20·5 versus 66·1 units/ml for CAR of 0·02 or less; P = 0·002), larger tumour size (3·2 versus 4·4 cm respectively; P = 0·031) and a higher rate of microvascular invasion (9 of 28 versus 25 of 44; P = 0·041). RFS and OS were shorter in patients with CAR above 0·02: hazard ratio (HR) 4·31 (95 per cent c.i. 2·02 to 10·63) and HR 4·80 (1·85 to 16·40) respectively. In multivariable analysis CAR above 0·02 was an independent prognostic factor of RFS (HR 3·29 (1·33 to 8·12); P < 0·001), but not OS. CONCLUSIONS: CAR was associated with prognosis in patients who had hepatic resection for ICC. John Wiley & Sons, Ltd 2020-09-21 /pmc/articles/PMC7709369/ /pubmed/32959537 http://dx.doi.org/10.1002/bjs5.50348 Text en © 2020 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of British Journal of Surgery Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Matsumoto, T.
Itoh, S.
Yoshizumi, T.
Kurihara, T.
Yoshiya, S.
Mano, Y.
Takeishi, K.
Harada, N.
Ikegami, T.
Soejima, Y.
Baba, H.
Mori, M.
C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma
title C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma
title_full C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma
title_fullStr C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma
title_full_unstemmed C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma
title_short C‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma
title_sort c‐reactive protein : albumin ratio in patients with resectable intrahepatic cholangiocarcinoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709369/
https://www.ncbi.nlm.nih.gov/pubmed/32959537
http://dx.doi.org/10.1002/bjs5.50348
work_keys_str_mv AT matsumotot creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT itohs creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT yoshizumit creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT kuriharat creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT yoshiyas creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT manoy creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT takeishik creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT haradan creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT ikegamit creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT soejimay creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT babah creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma
AT morim creactiveproteinalbuminratioinpatientswithresectableintrahepaticcholangiocarcinoma